Cargando…

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Currently, the incidence of cardiac events associated with ide-cel remains unclear. This wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Dae Hyun, Kumar, Abhishek, Mohammed, Turab, Peres, Lauren C., Alsina, Melissa, Bachmeier, Christina, Blue, Brandon J., Brayer, Jason, Chandrasekhar, Sanjay, Grajales Cruz, Ariel, De Avila, Gabe, Elmariah, Hany, Faramand, Rawan, Freeman, Ciara, Jain, Michael, Khadka, Sushmita, Khimani, Farhad, Liu, Hien, Nishihori, Taiga, Oswald, Laura B., Castaneda Puglianini, Omar A., Shain, Kenneth H., Smith, Eric, Baz, Rachid C., Locke, Frederick L., Oliveira, Guilherme H., Alomar, Mohammed, Hansen, Doris K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424134/
https://www.ncbi.nlm.nih.gov/pubmed/37307173
http://dx.doi.org/10.1182/bloodadvances.2023009766
_version_ 1785089608791359488
author Lee, Dae Hyun
Kumar, Abhishek
Mohammed, Turab
Peres, Lauren C.
Alsina, Melissa
Bachmeier, Christina
Blue, Brandon J.
Brayer, Jason
Chandrasekhar, Sanjay
Grajales Cruz, Ariel
De Avila, Gabe
Elmariah, Hany
Faramand, Rawan
Freeman, Ciara
Jain, Michael
Khadka, Sushmita
Khimani, Farhad
Liu, Hien
Nishihori, Taiga
Oswald, Laura B.
Castaneda Puglianini, Omar A.
Shain, Kenneth H.
Smith, Eric
Baz, Rachid C.
Locke, Frederick L.
Oliveira, Guilherme H.
Alomar, Mohammed
Hansen, Doris K.
author_facet Lee, Dae Hyun
Kumar, Abhishek
Mohammed, Turab
Peres, Lauren C.
Alsina, Melissa
Bachmeier, Christina
Blue, Brandon J.
Brayer, Jason
Chandrasekhar, Sanjay
Grajales Cruz, Ariel
De Avila, Gabe
Elmariah, Hany
Faramand, Rawan
Freeman, Ciara
Jain, Michael
Khadka, Sushmita
Khimani, Farhad
Liu, Hien
Nishihori, Taiga
Oswald, Laura B.
Castaneda Puglianini, Omar A.
Shain, Kenneth H.
Smith, Eric
Baz, Rachid C.
Locke, Frederick L.
Oliveira, Guilherme H.
Alomar, Mohammed
Hansen, Doris K.
author_sort Lee, Dae Hyun
collection PubMed
description Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Currently, the incidence of cardiac events associated with ide-cel remains unclear. This was a retrospective single-center observational study of patients treated with ide-cel for RRMM. We included all consecutive patients who received standard-of-care ide-cel treatment at least 1-month follow-up. Baseline clinical risk factors, safety profile, and responses were examined based on the development of a cardiac event. A total of 78 patients were treated with ide-cel, and 11 patients (14.1%) developed cardiac events: heart failure (5.1%), atrial fibrillation (10.3%), nonsustained ventricular tachycardia (3.8%), and cardiovascular death (1.3%). Only 11 of the 78 patients had repeat echocardiogram. Baseline risk factors associated with the development of cardiac events included being female sex and having poor performance status, λ light-chain disease, and advanced Revised International Staging System stage. Baseline cardiac characteristics were not associated with cardiac events. During index hospitalization after CAR-T, higher-grade (≥grade 2) cytokine release syndrome (CRS) and immune cell–associated neurologic syndrome were associated with cardiac events. In multivariable analyses, the hazard ratio for the association of the presence of cardiac events with overall survival (OS) was 2.66 and progression-free survival (PFS) was 1.98. Ide-cel CAR-T for RRMM was associated with similar cardiac events as other types of CAR-T. Worse baseline performance status and higher-grade CRS and neurotoxicity were associated with cardiac events after BCMA-directed CAR-T-cell therapy. Our results suggest that the presence of cardiac events may confer worse PFS or OS; although because of the small sample size, the power to detect an association was limited.
format Online
Article
Text
id pubmed-10424134
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-104241342023-08-15 Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma Lee, Dae Hyun Kumar, Abhishek Mohammed, Turab Peres, Lauren C. Alsina, Melissa Bachmeier, Christina Blue, Brandon J. Brayer, Jason Chandrasekhar, Sanjay Grajales Cruz, Ariel De Avila, Gabe Elmariah, Hany Faramand, Rawan Freeman, Ciara Jain, Michael Khadka, Sushmita Khimani, Farhad Liu, Hien Nishihori, Taiga Oswald, Laura B. Castaneda Puglianini, Omar A. Shain, Kenneth H. Smith, Eric Baz, Rachid C. Locke, Frederick L. Oliveira, Guilherme H. Alomar, Mohammed Hansen, Doris K. Blood Adv Clinical Trials and Observations Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Currently, the incidence of cardiac events associated with ide-cel remains unclear. This was a retrospective single-center observational study of patients treated with ide-cel for RRMM. We included all consecutive patients who received standard-of-care ide-cel treatment at least 1-month follow-up. Baseline clinical risk factors, safety profile, and responses were examined based on the development of a cardiac event. A total of 78 patients were treated with ide-cel, and 11 patients (14.1%) developed cardiac events: heart failure (5.1%), atrial fibrillation (10.3%), nonsustained ventricular tachycardia (3.8%), and cardiovascular death (1.3%). Only 11 of the 78 patients had repeat echocardiogram. Baseline risk factors associated with the development of cardiac events included being female sex and having poor performance status, λ light-chain disease, and advanced Revised International Staging System stage. Baseline cardiac characteristics were not associated with cardiac events. During index hospitalization after CAR-T, higher-grade (≥grade 2) cytokine release syndrome (CRS) and immune cell–associated neurologic syndrome were associated with cardiac events. In multivariable analyses, the hazard ratio for the association of the presence of cardiac events with overall survival (OS) was 2.66 and progression-free survival (PFS) was 1.98. Ide-cel CAR-T for RRMM was associated with similar cardiac events as other types of CAR-T. Worse baseline performance status and higher-grade CRS and neurotoxicity were associated with cardiac events after BCMA-directed CAR-T-cell therapy. Our results suggest that the presence of cardiac events may confer worse PFS or OS; although because of the small sample size, the power to detect an association was limited. The American Society of Hematology 2023-06-15 /pmc/articles/PMC10424134/ /pubmed/37307173 http://dx.doi.org/10.1182/bloodadvances.2023009766 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Trials and Observations
Lee, Dae Hyun
Kumar, Abhishek
Mohammed, Turab
Peres, Lauren C.
Alsina, Melissa
Bachmeier, Christina
Blue, Brandon J.
Brayer, Jason
Chandrasekhar, Sanjay
Grajales Cruz, Ariel
De Avila, Gabe
Elmariah, Hany
Faramand, Rawan
Freeman, Ciara
Jain, Michael
Khadka, Sushmita
Khimani, Farhad
Liu, Hien
Nishihori, Taiga
Oswald, Laura B.
Castaneda Puglianini, Omar A.
Shain, Kenneth H.
Smith, Eric
Baz, Rachid C.
Locke, Frederick L.
Oliveira, Guilherme H.
Alomar, Mohammed
Hansen, Doris K.
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
title Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
title_full Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
title_fullStr Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
title_full_unstemmed Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
title_short Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
title_sort cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
topic Clinical Trials and Observations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424134/
https://www.ncbi.nlm.nih.gov/pubmed/37307173
http://dx.doi.org/10.1182/bloodadvances.2023009766
work_keys_str_mv AT leedaehyun cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT kumarabhishek cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT mohammedturab cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT pereslaurenc cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT alsinamelissa cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT bachmeierchristina cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT bluebrandonj cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT brayerjason cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT chandrasekharsanjay cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT grajalescruzariel cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT deavilagabe cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT elmariahhany cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT faramandrawan cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT freemanciara cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT jainmichael cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT khadkasushmita cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT khimanifarhad cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT liuhien cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT nishihoritaiga cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT oswaldlaurab cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT castanedapuglianiniomara cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT shainkennethh cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT smitheric cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT bazrachidc cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT lockefrederickl cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT oliveiraguilhermeh cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT alomarmohammed cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma
AT hansendorisk cardiaceventsafterstandardofcareidecabtagenevicleucelforrelapsedandrefractorymultiplemyeloma